Browsing by Author "Ozdemir, Ilknur Yorgun"

Now showing 1 - 3 of 3

Evalution of Autoimmunity in Patients With Primary Cutaneous Vasculitis
(derman Medical Publ, 2014) Ozkol, Hatice Uce; Karadag, Ayse Serap; Calka, Omer; Akdeniz, Necmettin; Bulut, Gulay; Ozdemir, Ilknur Yorgun
Aim: In order to determine the clinical and etiological characteristics of primer cutaneous vasculitis and to evaluate its relation with immunological mechanisms, Material and Method: Twenty-eight hospitalized patients with cutaneous vasculitis between 2009-2011 in dermatology service were investigated retrospectively. Patients' age, gender, disease duration, associated symptoms, infection, and drug history were recorded. Results of immune fluorescence biopsy and all laboratory tests including detailed antibodies which were investigated for the differential diagnosis of vasculitis were given in percent (%) after recording to SPSS 13.0 statistical software. Results: Median age of the 28 patients (18 female, 10 male) was 37,89-v23,30 (5-84 age) years. 39.3% patients had neutrophilia, 67.9% patients had eosinophilia. Antinuclear antibodies (ANA) in 10 patients (35.746) were positive. Total IgE in 15 patients (53.6%), IgA in 9 patients (32.1%), IgG in ID patients (.35.7%) was higher than normal range. Thyroglobulin in 3 patients (10.746), antiTPO 4 patients (14.3%),antirubella IgG in 14 patients (50.0%) antitoxoplazma IgG in 10 patients (35.7%) were positive. Anticardiolipin antibodies, anti-ssa 1 and Anti-ssb2, only one patient (3.66/u) was positive. Discussion: lmmunoglobulins and ANA were determined positively in a high ratio in patients with cutaneous leucocytoclastic vasculitis however there was no systemic involvement, Autoimmunity may have an important role in pathogenesis. Moreover drugs were most frequently determined among etiological factors.
Increased Frequency of Pulmonary Hypertension in Psoriasis Patients
(Springer, 2008) Gunes, Yilmaz; Tuncer, Mustafa; Calka, Omer; Guntekin, Unal; Akdeniz, Necmettin; Simsek, Hakki; Ozdemir, Ilknur Yorgun
Several reports have demonstrated an association between psoriasis and cardiovascular diseases such as hypertension, valvular disease and arrhythmia. However, the data is scarce. Forty-seven psoriasis patients and 20 healthy people underwent transthoracic echocardiographic examination including pulse- and tissue Doppler analysis and 24-h ambulatory electrocardiographic monitoring including heart rate variability (HRV) analysis. Patients having systemic hypertension, diabetes mellitus, history of structural or ischemic heart disease, chronic obstructive pulmonary disease and any associated systemic disease were excluded. Psoriasis Area and Severity Index (PASI) was calculated and severe psoriasis was defined in the case of history of hospitalizations for psoriasis and/or getting systemic therapy. Mean age of the patients was 35.7 +/- 12.9 years and disease duration was 123.2 +/- 84.3 (3-360) months. PASI ranged from 0.4 to 34.0 (mean +/- SD: 7.1 +/- 6.6) and 20 (42.6%) patients had severe psoriasis. There were no significant differences between psoriasis patients and control group with respect to mean values of blood pressure, body mass index, lipid profile and cardiac dimensions. However, frequency of being overweight was significantly higher in psoriasis patients (42.6 vs. 10.0%, P = 0.011). No patient had valvular disease. Mild pulmonary hypertension (PH) (30-40 mmHg) was significantly more frequent in psoriasis patients (31.9 vs. 0%, P = 0.003). Pulse wave mitral Doppler deceleration and isovolumetric relaxation times were significantly longer in psoriasis patients (195.9 +/- 29.7 vs. 191.6 +/- 14.7 ms, P = 0.002 and 91.6 +/- 14.7 vs. 79.6 +/- 10.5 ms, P = 0.001, respectively). However, frequency of diastolic dysfunction was not significantly different than the control group (8.5 vs. 0%, P = 0.309). HRV parameters and frequency of supraventricular and ventricular premature beats were not significantly different between the groups. No patient had ventricular tachycardia. Echocardiographic follow-up of psoriasis patients may be important due to possible association of PH. However, incidences of structural heart disease and arrythmia are not increased in psoriasis according to our results.
The Relationship Between Fc Epsilon Receptor-1a a and Β ( Fcer1a and Fcer1b) ) Gene Polymorphisms in Patients With Chronic Urticaria Using Omalizumab
(Termedia Publishing House Ltd, 2024) Savas, Hulya; Ozkol, Hatice Uce; Gorgisen, Gokhan; Ozkol, Halil; Ates, Can; Metin, Ahmet; Ozdemir, Ilknur Yorgun
Introduction: Chronic urticaria requires well-defined treatment strategies in order to achieve a maximum treatment response and maintain the quality of life. Since 2014, omalizumab has been used in chronic urticaria. However, many studies showed that some patients are resistant to omalizumab. Aim: To determine the effects of single nucleotide changes in the FCER1A and FCER1B genes, which are thought to be related to resistance mechanisms, in our population of patients who have not responded to omalizumab treatment. Material and methods: We included 100 patients with chronic urticaria who were treated with omalizumab and 50 healthy individuals. Frequently observed gene polymorphisms, FCER1A (rs2251746) and FCER1B (rs569108), were examined in peripheral blood samples. The regions of rs2251746 and rs569108 gene polymorphisms were amplified using fluorescently labelled probes through real-time polymerase chain reaction (PCR). The analysis was performed bioinformatically via the SNP genotype profiling program. Results: There was no statistically significant relationship between FCER1A (rs2251746) and FCER1B (rs569108) gene polymorphisms in patients and their clinical, demographic characteristics, and the resistance to treatment (p > 0.05). In our study, the mean patient age was found to be higher in the CT group (44.71 +/- 12.5 years) compared to the TT group (37.34 +/- 11.5 years) only in the rs2251746 polymorphism (p < 0.05). Conclusions: In our study, there was no significant relationship between FCER1A and FCER1B gene polymorphisms and resistance to omalizumab therapy. Further, multicentre, large-scale studies are needed to support our results.